SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

efarindodekin alfa

XLO·Xilio Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Efarindodekin alfa is in Phase 2 testing. Assuming successful trials and regulatory review, potential approval would likely be several years away (2029 or later), though the Gilead partnership could accelerate development if Gilead exercises its option.
Why 3/10
No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for efarindodekin alfa within the next ~12 months. The Phase 2 trial is ongoing with no announced data readout date. The drug is one of several pipeline assets at Xilio, which also includes XTX501 (Phase 1/2, data expected Q4 2027) and XTX602 (preclinical).
Actionable Insight NEUTRAL

Efarindodekin alfa (XTX301) is in an ongoing Phase 2 monotherapy trial with no announced data readout date. The next major pipeline catalyst for Xilio is the XTX501 Phase 1 data expected in Q4 2027. Investors should watch for any update on XTX301 Phase 2 enrollment progress or potential Gilead exercise of its option to take over development, which would trigger a $75 million transition fee.

Price Chart

Loading chart...

Executive Summary

Efarindodekin alfa (XTX301) is Xilio Therapeutics' tumor-activated (masked) IL-12 immunotherapy, currently in a Phase 1/2 clinical trial for advanced solid tumors. Phase 1 data presented in late 2025 showed promising monotherapy anti-tumor activity and a well-tolerated safety profile at doses over 100-fold higher than the maximum tolerated dose of recombinant human IL-12. The Phase 2 portion was initiated in September 2025. The program is partnered with Gilead Sciences under an exclusive license agreement that includes a $17.5 million milestone already achieved and a potential $75 million transition fee if Gilead exercises its option. Xilio's stock trades at $8.53 with a mean analyst price target of $18, but the drug has no announced near-term data readout catalyst.

How It Works

Efarindodekin alfa is a "masked" version of interleukin-12 (IL-12), a naturally occurring protein that stimulates the immune system to attack cancer cells. The masking technology keeps the drug inactive until it reaches the tumor environment, where enzymes activate it. This design aims to deliver the potent anti-cancer effects of IL-12 while avoiding the severe side effects that have historically limited this approach.

Trial Status

The Phase 2 portion of a Phase 1/2 clinical trial was initiated in September 2025, evaluating efarindodekin alfa as a monotherapy in patients with advanced solid tumors. Phase 1 dose escalation data were presented at the SITC 2025 annual meeting, demonstrating a favorable safety profile and early signs of anti-tumor activity.

The Two-Sided Case

▲ Bull Case4
Phase 1 data showed efarindodekin alfa was generally well-tolerated at doses over 100-fold greater than the maximum tolerated dose of recombinant human IL-12, with primarily Grade 1-2 treatment-related adverse events, suggesting the masking technology may solve IL-12's historical toxicity problem.
Phase 1 data demonstrated promising monotherapy anti-tumor activity in advanced solid tumors, a difficult-to-treat patient population.
The program is backed by Gilead Sciences through an exclusive license agreement, with a $17.5M milestone already achieved and a potential $75M transition fee if Gilead exercises its option to take over development.
Analyst consensus is strongly positive: 5 of 6 analysts rate the stock Buy or Strong Buy, with a mean price target of $18 (111% upside from the $8.53 close).
▼ Bear Case4
Efarindodekin alfa is still in early-to-mid-stage clinical development (Phase 2) with no approved products, meaning a high risk of clinical failure. IL-12 has historically been a difficult target with significant toxicity challenges.
No specific data readout date has been announced for the Phase 2 trial, creating an uncertain timeline for the next catalyst.
Xilio had only $5.9M in Q3 2026 revenue and a net loss, with cash runway extending only into Q1 2027, creating potential financing risk if milestones are delayed.
Gilead has an option but not an obligation to take over the program; if Phase 2 data disappoints, Gilead could walk away, removing a key partnership validation.

Upcoming Catalysts

  • No specific data readout date has been announced for the XTX301 Phase 2 trial. The next major pipeline catalyst for Xilio is initial Phase 1 data for XTX501, expected in the fourth quarter of 2027. Gilead's decision on whether to exercise its option to take over efarindodekin alfa development (triggering a $75M transition fee) is a potential binary catalyst but has no announced timeline.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Xilio Therapeutics, Inc. PRESS-RELEASE XLO ·Originating report

Sources · 8

Hover a chip for the title
1 finanznachrichten.de2 menafn.com3 nasdaq.com4 markets.businessinsider.com5 rttnews.com6 streetinsider.com7 nasdaq.com8 markets.financialcontent.com